Steris (STE) Tops Q2 EPS by 5c; reaffirms FY25 outlook

Steris (NYSE: STE) reported Q2 EPS of $2.03, $0.05 better than the analyst estimate of $1.98. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.27 billion.

GUIDANCE

Steris sees FY2025 EPS of $9.05 to $9.25 versus the consensus of $9.14.

For fiscal 2025, the Company continues to expect as reported revenue from continuing operations to increase 6.5-7.5%. Based on forward rates through March 31, 2025, currency is expected to be neutral to revenue in fiscal 2025. Constant currency organic revenue from continuing operations is anticipated to increase 6-7%.

For earnings history and earnings-related data on Steris (STE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Enanta Pharma loses appeal in Pfizer Paxlovid patent case
• Lockheed Martin wins $8.4B missile contract modification